{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-062766","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2024-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.265982+00:00","generated_at":"2026-05-31T19:06:51.435766+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Longeveron raises $9.0M via registered direct offering of 2.24M shares at $4.025; warrants at $3.90","bullets":["Gross proceeds of approximately $9.0M from sale of 2,236,026 shares and concurrent private placement of warrants for 2,236,026 shares.","Warrants exercisable immediately at $3.90 per share for 24 months; placement agent fees of 7% plus warrants at $5.0313.","Net proceeds to fund Lomecel-B clinical programs for HLHS and Alzheimer's disease, regulatory approvals, and working capital.","Closing expected on July 19, 2024; H.C. Wainwright acted as exclusive placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-062766","json":"https://secwatch.observer/filing/0001213900-24-062766.json","markdown":"https://secwatch.observer/filing/0001213900-24-062766.md","text":"https://secwatch.observer/filing/0001213900-24-062766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390024062766/0001213900-24-062766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390024062766/ea0209682-8k_longe.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:06:51.435766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}